Gryphon Financial Partners LLC Purchases 2,439 Shares of Moderna, Inc. $MRNA

Posted by Brian Himes on Nov 11th, 2026

Gryphon Financial Partners LLC purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) during the third quarter, HoldingsChannel reports. The fund purchased 2,439 shares of the company’s stock, valued at approximately $470,000.

Other institutional investors have also bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Moderna in the 2nd quarter worth $2,142,877,000. Theleme Partners LLP purchased a new stake in shares of Moderna during the 2nd quarter valued at about $564,272,000. Wellington Management Group LLP raised its position in shares of Moderna by 4.4% during the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock valued at $172,384,000 after buying an additional 103,977 shares in the last quarter. Merck & Co. Inc. purchased a new stake in shares of Moderna during the 2nd quarter valued at about $161,642,545. Finally, Bamco Inc. NY bought a new position in shares of Moderna in the 2nd quarter valued at about $139,317,000. Institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several recent research reports. Singular Research upgraded Moderna to a “hold” rating in a research report on Wednesday, September 23rd. Sanford C. Bernstein restated a “market perform” rating on shares of Moderna in a research report on Friday, September 25th. The Goldman Sachs Group raised their price objective on Moderna from $137.00 to $195.00 and gave the company a “neutral” rating in a research note on Monday. Bradesco Corretora upgraded Moderna to an “outperform” rating in a report on Friday, August 28th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $150.00 target price (up from $60.00) on shares of Moderna in a research report on Wednesday, August 19th. Six investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $113.75.

Check Out Our Latest Stock Analysis on Moderna

Insider Activity

In other news, President Stephen Hoge sold 40,294 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22. Following the transaction, the president directly owned 1,525,858 shares in the company, valued at approximately $219,921,913.54. This represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the transaction, the insider owned 74,129 shares in the company, valued at approximately $10,374,353.55. This represents a 4.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is currently owned by insiders.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $250.83 on Wednesday. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $280.80. The company has a market capitalization of $101.49 billion, a price-to-earnings ratio of -35.33 and a beta of 1.16. The firm’s 50-day moving average is $196.68 and its 200 day moving average is $93.60.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $890.25 million. During the same quarter last year, the firm earned ($0.51) earnings per share. The firm’s quarterly revenue was up 29.2% compared to the same quarter last year. Research analysts predict that Moderna, Inc. will post -5.69 EPS for the current year.

Key Moderna News

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Moderna reported third-quarter revenue of about $1.3 billion, up 29% year over year and ahead of expectations, and raised its 2026 revenue-growth outlook to 15%–25%. Lower costs and respiratory-vaccine gains also supported the improved outlook. Why is Moderna stock soaring today?
Positive Sentiment: Investors also have a potential longer-term catalyst in personalized cancer vaccine intismeran. Phase 3 results reportedly showed a 42% reduction in melanoma recurrence or death, and Moderna is targeting an FDA filing by year-end 2026, which could lead to a decision in 2027. Can Moderna’s first cancer therapy win FDA approval in 2027?
Neutral Sentiment: Moderna is scheduled to present at the Jefferies Global Health Care Conference on November 18. The event could provide updates, but the announcement itself does not change the company’s outlook. Moderna to present at upcoming conference
Negative Sentiment: Despite the earnings beat, nearly all of Moderna’s revenue still comes from COVID-related products, leaving investors focused on the challenge of building durable sales beyond the pandemic market. That concern may weigh more heavily after the stock’s sharp recent run. Moderna’s Q3 numbers may not be enough to make the stock a buy
Negative Sentiment: Valuation is another headwind: Goldman Sachs raised its price target but kept a neutral rating, while a separate analysis put fair value well below the prevailing share price. Brookline also made modest reductions to its long-term earnings estimates, despite maintaining a Buy rating.

Moderna Profile

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.